TherapeuticsMD, Inc.TXMDNASDAQ
Loading
Operating Cash Flow Growth Recovery in ProgressRecovering
Percentile Rank90
5Y CAGR+41.6%
Year-over-Year Change
Year-over-year operating cash flow growth rate
5Y CAGR
+41.6%/yr
Long-term compound
Percentile
P90
Near historical high
vs 5Y Ago
5.7x
Strong expansion
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q3 2025 | 222.84% |
| Q2 2025 | -52.77% |
| Q1 2025 | 5616.67% |
| Q4 2024 | 106.49% |
| Q3 2024 | -120.69% |
| Q2 2024 | 8027.27% |
| Q1 2024 | 100.14% |
| Q4 2023 | -219.39% |
| Q3 2023 | 47.43% |
| Q2 2023 | 85.92% |
| Q1 2023 | -155.50% |
| Q4 2022 | 473.96% |
| Q3 2022 | -91.01% |
| Q2 2022 | 492.22% |
| Q1 2022 | 25.36% |
| Q4 2021 | -3.49% |
| Q3 2021 | -44.06% |
| Q2 2021 | 30.87% |
| Q1 2021 | -26.58% |
| Q4 2020 | 10.95% |
| Q3 2020 | 39.15% |
| Q2 2020 | -43.06% |
| Q1 2020 | 23.01% |
| Q4 2019 | -93.72% |
| Q3 2019 | 48.09% |
| Q2 2019 | -32.36% |
| Q1 2019 | -35.60% |
| Q4 2018 | 17.39% |
| Q3 2018 | -36.55% |
| Q2 2018 | -26.97% |
| Q1 2018 | 5.56% |
| Q4 2017 | -24.70% |
| Q3 2017 | 8.02% |
| Q2 2017 | 11.62% |
| Q1 2017 | -31.42% |
| Q4 2016 | 16.92% |
| Q3 2016 | -22.70% |
| Q2 2016 | 21.04% |
| Q1 2016 | -16.82% |
| Q4 2015 | 9.92% |